Therapeutic applications of antisense DNA in the treatment of human leukemia.
Gewirtz
A M
AM
Department of Pathology, University of Pennsylvania School of Medicine, Philadelphia 19104.
D001854:Bone Marrow Cells; D002478:Cells, Cultured; D016044:Fusion Proteins, bcr-abl / Q000235:genetics; D006410:Hematopoiesis / Q000235:genetics; D006412:Hematopoietic Stem Cells / Q000166:cytology; D006801:Humans; D007938:Leukemia / Q000188:drug therapy*; D007963:Leukocytes, Mononuclear / Q000166:cytology; D009838:Oligodeoxyribonucleotides / Q000627:therapeutic use*; D016376:Oligonucleotides, Antisense / Q000627:therapeutic use*; D009857:Oncogenes / Q000187:drug effects*; D011518:Proto-Oncogene Proteins / Q000235:genetics; D019009:Proto-Oncogene Proteins c-kit; D020794:Receptor Protein-Tyrosine Kinases / Q000235:genetics; D016184:Receptors, Colony-Stimulating Factor / Q000235:genetics
D009838:Oligodeoxyribonucleotides; D016376:Oligonucleotides, Antisense; D011518:Proto-Oncogene Proteins; D016184:Receptors, Colony-Stimulating Factor; D019009:Proto-Oncogene Proteins c-kit; D020794:Receptor Protein-Tyrosine Kinases; D016044:Fusion Proteins, bcr-abl